X4 Pharmaceuticals Company Insiders
XFOR Stock | USD 2.12 0.62 41.33% |
Slightly above 75% of X4 Pharmaceuticals' corporate insiders are selling. The analysis of the overall insider sentiment regarding X4 Pharmaceuticals suggests that many insiders are alarmed. X4 Pharmaceuticals employs about 143 people. The company is managed by 14 executives with a total tenure of roughly 12 years, averaging almost 0.0 years of service per executive, having 10.21 employees per reported executive.
Paula Ragan CEO President CEO, Secretary, Director |
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
2025-05-16 | Mark Baldry | Acquired 1032 @ 2.48 | View | ||
2025-01-24 | Paula Ragan | Disposed 2549 @ 13.5 | View | ||
2024-10-15 | Paula Ragan | Disposed 1063 @ 16.8 | View | ||
2024-10-07 | Paula Ragan | Disposed 7981 @ 16.5 | View |
Monitoring X4 Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. X4 Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5861) % which means that it has lost $0.5861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2175 %, meaning that it created $1.2175 on every $100 dollars invested by stockholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/24/2025, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.34. At this time, X4 Pharmaceuticals' Net Tangible Assets are relatively stable compared to the past year. As of 07/24/2025, Debt To Assets is likely to grow to 0.56, while Total Assets are likely to drop slightly above 108.3 M.As of 07/24/2025, Common Stock Shares Outstanding is likely to grow to about 211.1 M, though Net Loss is likely to grow to (82.4 M).
X4 Pharmaceuticals Workforce Comparison
X4 Pharmaceuticals is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 713. X4 Pharmaceuticals totals roughly 143 in number of employees claiming about 20% of equities under Health Care industry.
X4 Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.33.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.91 | 0.79 |
|
|
X4 Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific X4 Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on X4 Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, X4 Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wyzga Michael S over a month ago Acquisition by Wyzga Michael S of 1500 shares of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Thoren Natasha Fay over two months ago Insider Trading | ||
Baldry Mark over two months ago Acquisition by Baldry Mark of 1032 shares of X4 Pharmaceuticals at 2.482 subject to Rule 16b-3 | ||
Paula Ragan over three months ago Acquisition by Paula Ragan of 169940 shares of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Arbet-engels Christophe over six months ago Disposition of 11624 shares by Arbet-engels Christophe of X4 Pharmaceuticals at 0.4546 subject to Rule 16b-3 | ||
Arbet-engels Christophe over six months ago Acquisition by Arbet-engels Christophe of 25831 shares of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Mary DiBiase over six months ago Disposition of 1578 shares by Mary DiBiase of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Paula Ragan over six months ago Disposition of 31897 shares by Paula Ragan of X4 Pharmaceuticals at 0.562 subject to Rule 16b-3 |
X4 Pharmaceuticals Notable Stakeholders
A X4 Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as X4 Pharmaceuticals often face trade-offs trying to please all of them. X4 Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting X4 Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paula Ragan | President CEO, Secretary, Director | Profile | |
Richard MD | Chairman Founder | Profile | |
Adam Mostafa | CFO, Treasurer, Assistant Secretary | Profile | |
Brian Bowersox | VP Controller | Profile | |
Renato Skerlj | Founder | Profile | |
Arthur Taveras | Chief Officer | Profile | |
Murray MD | Interim Director | Profile | |
Mark MBA | Chief Officer | Profile | |
MBA MD | Chief Officer | Profile | |
Natasha Esq | Chief Officer | Profile | |
Robert Arbeit | Senior Research | Profile | |
Mary DiBiase | Chief Officer | Profile | |
Keith MD | Founder Board | Profile | |
Pharm MPH | Vice Communications | Profile |
About X4 Pharmaceuticals Management Performance
The success or failure of an entity such as X4 Pharmaceuticals often depends on how effective the management is. X4 Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XFOR management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XFOR management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.31) | (0.33) | |
Return On Capital Employed | (0.32) | (0.34) | |
Return On Assets | (0.26) | (0.27) | |
Return On Equity | (1.69) | (1.78) |
X4 Pharmaceuticals Workforce Analysis
Traditionally, organizations such as X4 Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare X4 Pharmaceuticals within its industry.X4 Pharmaceuticals Manpower Efficiency
Return on X4 Pharmaceuticals Manpower
Revenue Per Employee | 17.9K | |
Revenue Per Executive | 182.6K | |
Net Loss Per Employee | 261.9K | |
Net Loss Per Executive | 2.7M | |
Working Capital Per Employee | 554.5K | |
Working Capital Per Executive | 5.7M |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.